Cabaletta Bio

[Not Yet Scheduled]
Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Our proprietary technology utilizes chimeric autoantibody receptor, or CAAR, T cells that are designed to selectively bind and eliminate B cells that produce disease-causing autoantibodies (pathogenic B cells) while sparing normal B cells. Our lead CAAR T cell product candidate was designed based on chimeric antigen receptor, or CAR, T cell technology that has been successfully developed and is marketed for the treatment of B cell cancers. During the past two years, using our CABA platform, we have discovered and are advancing four product candidates that have demonstrated specific and selective target engagement in vitro. Our lead product candidate is in development to treat patients with mucosal pemphigus vulgaris, or mPV.
Ticker:
CABA
Exchange:
Nasdaq
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Pennsylvania
Company HQ Country:
United States
Year Founded:
Not Provided
Main Therapeutic Focus:
Lead Product in Development:
DSG3-CAART for Mucosal PV
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
CEO, President and Chairman
Cabaletta Bio